Related Experiment Videos

Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms

K-S Lee1, Y-S Lee, J C Kim

  • 1Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

International Journal of Clinical Practice
|June 16, 2012
PubMed
Abstract

Insights

Patient-reported goal achievement (GA) in overactive bladder (OAB) treatment is a valuable measure. This study found GA correlated strongly with treatment benefit and patient satisfaction, highlighting its importance beyond traditional metrics.

Area of Science:

  • Urology
  • Patient-Reported Outcomes
  • Pharmacological Treatment

Background:

  • Standardized outcome measures in overactive bladder (OAB) treatment may not reflect patient priorities.
  • Patient-centered care necessitates assessing individual treatment goals and their achievement.

Purpose of the Study:

  • To evaluate patient-reported goals and goal achievement (GA) during antimuscarinic treatment for OAB.
  • To compare GA with traditional outcome measures and assess its correlation with treatment benefit and satisfaction.

Main Methods:

  • Adult patients with OAB received oxybutynin (10-30 mg) for 12 weeks.
  • Individual treatment goals were identified pre-treatment, and GA was assessed post-treatment using a Likert scale (0-5).
  • Correlation analysis was performed between GA, traditional OAB measures, treatment benefit, and satisfaction.

Main Results:

  • 303 patients identified goals, primarily symptom relief (72.3%), quality of life improvement (13.5%), and reduced coping behaviors (14.2%).
  • 42% of patients achieved their goals (score 4-5), with a median GA score of 3.
  • Older age negatively impacted GA; GA showed the strongest correlation with treatment benefit and satisfaction.

Conclusions:

  • Goal achievement (GA) is a meaningful outcome measure for OAB patients.
  • GA effectively captures individual patient priorities and reflects overall treatment success.
  • Incorporating GA into OAB treatment assessment enhances patient-centered care and outcome evaluation.

Related Concept Videos

Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs like...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...